keyword
MENU ▼
Read by QxMD icon Read
search

Liver transplant, hcc,

keyword
https://www.readbyqxmd.com/read/28922192/differentiation-of-malignant-thrombus-from-bland-thrombus-of-the-portal-vein-in-patient-with-hepatocellular-carcinoma-on-18f-fdg-pet-ct
#1
Krishan Kant Agarwal, Dipalkumar Shah, Neha Shah, Manas Mayank
Hepatocellular carcinoma carries a high risk of invasion of the portal vein. Neoplastic and bland portal vein thrombi discrimination is of great clinical significance for determining the therapeutic approach, predicting survival, and assessing candidates for liver transplantation. F-FDG PET/CT may be helpful in discriminating between malignant and portal vein thrombi. We present the case of a 61-year old man who presented with hepatocellular carcinoma with portal vein involvement. F-FDG PET/CT has a role in differentiating malignant from benign portal vein thrombosis...
September 15, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28921807/the-italian-compassionate-use-of-sofosbuvir-in-hcv-patients-waitlisted-for-liver-transplantation-a-national-real-life-experience
#2
Silvia Martini, Maria Francesca Donato, Chiara Mazzarelli, Maria Rendina, Ubaldo Visco-Comandini, Daniela Filì, Alice Gianstefani, Stefano Fagiuoli, Mario Melazzini, Simona Montilla, Luca Pani, Sandra Petraglia, Pierluigi Russo, Maria Paola Trotta, Paola Carrai, Paolo Caraceni
BACKGROUND & AIMS: This study aimed to assess the real-life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program. METHODS: Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks. RESULTS: Of 100 transplanted patients, 51 were HCV-RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for <4 weeks or still viremic at transplant: 34 patients continued treatment after LT (bridging therapy) (SVR12: 88%), while 15 stopped treatment (SVR12: 53%)...
September 16, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28920178/impact-of-splenic-volume-and-splenectomy-on-prognosis-of-hepatocellular-carcinoma-within-milan-criteria-after-curative-hepatectomy
#3
Kazuki Takeishi, Hirofumi Kawanaka, Shinji Itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Ken Shirabe, Yoshihiko Maehara
BACKGROUND: The prognosis of hepatocellular carcinoma (HCC) with portal hypertension (PH) is very poor. Splenomegaly is considered important evidence of PH. Our aim was to clarify the prognostic value of splenic volume (SV) and the effect of splenectomy on the prognosis of HCC within the Milan criteria after curative hepatectomy. METHODS: In this single-center retrospective study, we reviewed 160 patients with HCC that met the Milan criteria, including 138 who had undergone hepatectomy and 22 who had undergone hepatectomy and splenectomy between July 2004 and December 2010...
September 18, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28918403/successful-twice-interrupted-therapy-of-hcv-infection-in-patients-with-cirrhosis-with-hepatocellular-carcinoma-before-and-after-liver-transplantation
#4
Anna Szymanek-Pasternak, Karolina Rostkowska, Krzysztof Simon
We are presenting the case study of the patient diagnosed at the age of 37 with liver cirrhosis due to genotype 1b hepatitis C virus infection. At the age of 46, he was diagnosed with hepatocellular carcinoma with subsequent resection of the tumour in May 2015. In December 2015, the treatment was started with ombitasvir, paritaprevir/ritonavir and dasabuvir (3D) with ribavirin (RBV) 1000 mg per day. After 24 days of this treatment, the patient received a deceased donor liver transplantation, followed by 18-day interruption of 3D therapy...
September 15, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28915639/heptamethine-carbocyanine-dz-1-dye-for-near-infrared-fluorescence-imaging-of-hepatocellular-carcinoma
#5
Jiaze An, Ningning Zhao, Caiqin Zhang, Yong Zhao, Dengxu Tan, Ya Zhao, Bing Bai, Hai Zhang, Boyang Jason Wu, Changhong Shi
Near-infrared fluorescence (NIRF) dyes have recently emerged as promising tools for non-invasive imaging of different types of cancers. Here, we explored the potential utility of a NIRF DZ-1 dye, with dual imaging and tumour targeting functions, in hepatocellular carcinoma (HCC). We showed the preferential uptake of DZ-1 by HCC cells in vitro and in derived subcutaneous/orthotopic tumour xenografts, accompanied by a minimal effect on normal cells. DZ-1 simplified tumour growth profiling as well, since we were able to correlate NIRF signals with tumour volume and/or tumour-emitting luminescence in mice...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28914862/-liver-diseases-the-pathogenetic-role-of-the-gut-microbiome-and-the-potential-of-treatment-for-its-modulation
#6
K A Aitbaev, I T Murkamilov, V V Fomin
The paper gives an update on the role of the gut microbiome (GM) in the development of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, alcoholic liver disease, liver cirrhosis (LC), and its complications, such as hepatic encephalopathy (HE) and hepatocellular carcinoma (HCC), and discusses the possibilities of its correction with prebiotics, probiotics, synbiotics, antibiotics, and fecal microbiota transplantation (FMT). The pathophysiology of the liver diseases in question demonstrates some common features that are characterized by pathogenic changes in the composition of the gastrointestinal tract microflora, by intestinal barrier impairments, by development of endotoxemia, by increased liver expression of proinflammatory factors, and by development of liver inflammation...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28914714/radiologically-undetected-hepatocellular-carcinoma-in-patients-undergoing-liver-transplantation-an-immunohistochemical-correlation-with-li-rads-score
#7
Wei Xiong, Gregory Cheeney, Sooah Kim, Violetta Kolesnikova, Brooke Henninger, Jacob Alexander, Paul E Swanson, Melissa P Upton, Camtu D Truong, Matthew M Yeh
Orthotopic liver transplantation is the best option for patients with carefully selected unresectable disease because of underlying liver dysfunction. The 5-year survival rate after orthotopic liver transplantation for early detected hepatocellular carcinoma (HCC) is high, and a similar or even higher rate is reported in those with radiologically undetected HCC. This study evaluated and compared the histologic features of pretransplant radiologically undetected (14 patients, 25 tumors) versus detected (36 patients, 45 tumors) HCCs...
September 13, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28905009/living-donor-liver-transplantation-for-hepatocellular-cancer-an-almost-exclusive-eastern-procedure
#8
REVIEW
Rafael S Pinheiro, Daniel R Waisberg, Lucas S Nacif, Vinicius Rocha-Santos, Rubens M Arantes, Liliana Ducatti, Rodrigo B Martino, Quirino Lai, Wellington Andraus, Luiz A C D'Albuquerque
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and it is linked with chronic liver disease. Liver transplantation (LT) is the best curative treatment modality, since it can cure simultaneously the underlying liver disease and HCC. Milan criteria (MC) are the benchmark for selecting patients with HCC for LT, achieving up to 91% 1-year survival post transplantation. However, when considering intention-to-treat (ITT) rates are substantially lower, mainly due dropout. Additionally, Milan criteria (MC) are too restrictive and more inclusive criteria have been reported with good outcomes...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28901345/-acute-alcoholic-hepatitis
#9
Gianni Testino, Emanuele Scafato, Valentino Patussi
Chronic alcohol related liver disease is characterized by a cascade of events defined as follows: steatosis, steatohepatitis/steatofibrosi, cirrhosis and hepatocellular carcinoma. On one of these histologic patterns may overlap acute alcoholic hepatitis (AAE) (mild, moderate, severe). Severe AAE can cause a severe clinical picture: jaundice with a duration of less than three months, jaundice in the first decompensation event, serum bilirubin higher than 5 mg/dL, ratio AST/ALT >2:1, AST less than 500 IU/L ALT <300 IU/L, neutrophil leukocytosis and increased GGT...
September 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28900709/pretransplant-intra-arterial-liver-directed-therapy-does-not-increase-the-risk-of-hepatic-arterial-complications-in-liver-transplantation-a-single-center-10-year-experience
#10
Joseph R Kallini, Ahmed Gabr, Rehan Ali, Nadine Abouchaleh, Ahsun Riaz, Talia Baker, Laura Kulik, Juan Caicedo, Riad Salem, Robert J Lewandowski
PURPOSE: To investigate the association between pretransplant intra-arterial liver-directed therapy (IAT) for hepatocellular carcinoma (HCC) and hepatic arterial complications (HAC) in orthotopic liver transplantation (OLT) [namely hepatic artery thrombosis (HAT) and/or the need for hepatic arterial conduit]. METHODS: A total of 175 HCC patients (mean age: 60 years) underwent IAT with either transarterial chemoembolization or yttrium-90 (90Y) transarterial radioembolization prior to OLT between 2003 and 2013...
September 12, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28900245/the-role-of-metronomic-capecitabine-for-treatment-of-recurrent-hepatocellular-carcinoma-after-liver-transplantation
#11
Matteo Ravaioli, Alessandro Cucchetti, Antonio Daniele Pinna, Vanessa De Pace, Flavia Neri, Maria Aurelia Barbera, Lorenzo Maroni, Giorgio Frega, Andrea Palloni, Stefania De Lorenzo, Maria Cristina Ripoli, Maria Abbondanza Pantaleo, Matteo Cescon, Massimo Del Gaudio, Giovanni Brandi
The management of recurrent hepatocellular carcinoma untreatable with surgical options is based on systemic therapy with sorafenib. Due to the high rates of adverse events connected to the therapy with sorafenib, metronomic capecitabine seems a promising strategy for these patients. We analyzed the data of 38 patients with hepatocellular carcinoma recurrent after liver transplantation performed at our center. We compared the outcome of 17 patients receiving metronomic capecitabine versus 20 patients experiencing best supportive care and versus the data of the literature about treatment with sorafenib...
September 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28894794/short-and-long-term-outcomes-of-de-novo-liver-transplant-patients-treated-with-once-daily-prolonged-release-tacrolimus
#12
Yuichiro Okumura, Takehiro Noda, Hidetoshi Eguchi, Yoshifumi Iwagami, Daisaku Yamada, Tadafumi Asaoka, Hiroshi Wada, Koichi Kawamoto, Kunihito Gotoh, Yutaka Takeda, Masahiro Tanemura, Shigeru Marubashi, Koji Umeshita, Yuichiro Doki, Masaki Mori
BACKGROUND: Tacrolimus is the key immunosuppressive drug for liver transplantation. Once-daily prolonged-release tacrolimus (TAC-PR) exhibits good drug adherence but has difficulty controlling the trough level in the early phase of liver transplantation. The aim of this study was to compare the feasibility and efficacy of immediately starting oral TAC-PR versus traditional twice-daily tacrolimus (TAC-BID) in de novo liver transplantation recipients. METHODS: The study included 28 patients treated with conventional TAC-BID and 60 patients treated with TAC-PR (median follow-up 70...
September 2017: Transplantation Direct
https://www.readbyqxmd.com/read/28894793/infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-treated-with-a-single-high-dose-y90-radioembolization-and-subsequent-liver-transplantation-without-a-recurrence
#13
Meaghan S Dendy, Juan C Camacho, Johannes M Ludwig, Alyssa M Krasinskas, Stuart J Knechtle, Hyun S Kim
BACKGROUND: Infiltrative hepatocellular carcinoma with macrovascular invasion is a relatively rare presentation and usually fatal disease. METHODS: Both patients exceeded Milan and University of California-San Francisco (UCSF) criteria, and per Barcelona Clinic Liver Cancer group guidelines, they were enrolled in a prospective open-label radioembolization phase II trial that gave them optimized lobar doses of Yttrium-90 as solely the first-line therapy without concomitant or additional pharmacological or locoregional therapies...
September 2017: Transplantation Direct
https://www.readbyqxmd.com/read/28894464/inflammatory-markers-as-prognostic-factors-of-survival-in-patients-affected-by-hepatocellular-carcinoma-undergoing-transarterial-chemoembolization
#14
A Rebonato, L Graziosi, D Maiettini, E Marino, V De Angelis, L Brunese, S Mosca, G Metro, M Rossi, G Orgera, M Scialpi, A Donini
INTRODUCTION: Transarterial chemoembolization (TACE) is a good choice for hepatocellular carcinoma (HCC) treatment when surgery and liver transplantation are not feasible. Few studies reported the value of prognostic factors influencing survival after chemoembolization. In this study, we evaluated whether preoperative inflammatory factors such as neutrophil to lymphocyte ratio and platelet to lymphocyte ratio affected our patient survival when affected by hepatocellular carcinoma. METHODS: We retrospectively evaluated a total of 72 patients with hepatocellular carcinoma that underwent TACE...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28890407/treatment-for-intrahepatic-recurrence-after-curative-resection-of-hepatocellular-carcinoma-salvage-liver-transplantation-or-re-resection-radiofrequency-ablation
#15
Xiaoyun Zhang, Chuan Li, Tianfu Wen, Wei Peng, Lunan Yan, Jiayin Yang
OBJECTIVE: The optimal treatment strategy for patients with recurrent hepatocellular carcinoma (HCC) remains unclear. This study was designed to investigate the outcomes of salvage liver transplantation (SLT) and re-resection (RR)/radiofrequency ablation (RFA) with respect to the time to recurrence after initial curative resection. METHODS: Between 2007 and 2016, 756 patients underwent curative hepatectomy for HCC in accordance with the Milan criteria. Among them, 152 experienced an intrahepatic recurrence and underwent SLT (n = 36) and RR/RFA (n = 116)...
September 7, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28888776/living-donor-liver-transplantation-for-hepatocellular-carcinoma-results-of-prospective-patient-selection-by-kyushu-university-criteria-in-7-years
#16
Hideaki Uchiyama, Shinji Itoh, Tomoharu Yoshizumi, Toru Ikegami, Norifumi Harimoto, Yuji Soejima, Noboru Harada, Kazutoyo Morita, Takeo Toshima, Takashi Motomura, Yoshihiko Maehara
BACKGROUND: Expanding patient selection beyond the Milan criteria in living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) has long been a matter for debate. We have used the Kyushu University Criteria - maximum tumor diameter <5 cm or des-γ-carboxy prothrombin <300 mAU/ml - in LDLT for HCC since June 2007. The aim of the present study was to present the results of our prospective patient selection by Kyushu University Criteria and to confirm whether or not our criteria were justified...
September 7, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/28885774/small-for-size-grafts-increase-recurrence-of-hepatocellular-carcinoma-in-liver-transplantation-beyond-milan-criteria
#17
Eung Chang Lee, Seong Hoon Kim, Jae Ryong Shim, Sang-Jae Park
BACKGROUND: Living donor liver transplantation (LDLT) has been reported to have high rates of hepatocellular carcinoma (HCC) recurrence compared to deceased donor liver transplant (DDLT). This has been assumed to be due to the frequent use of small-for-size grafts (SFSG) in LDLT rather than DDLT, but the relationship between graft size and prognosis remains controversial. This study aimed to clarify the effect of SFSG on the oncologic outcomes of patients with HCC who underwent LDLT. METHODS: Between January 2005 and December 2015, 597 consecutive patients underwent LDLT...
September 8, 2017: Liver Transplantation
https://www.readbyqxmd.com/read/28884605/nanomedicines-a-theranostic-approach-for-hepatocellular-carcinoma
#18
Afreen Usmani, Anuradha Mishra, Mohd Ahmad
The liver is an imperative organ of tremendous importance concerned with maintenance of metabolic functions and detoxification of exogenous and endogenous challenges like xenobiotics, viral infections and chronic alcoholism. Liver diseases particularly hepatitis B virus infections, liver cirrhosis and hepatocellular carcinoma continue to pose a significant health challenge worldwide due to the lack of therapeutic management options besides liver resection and transplantation. Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer mortality worldwide...
September 8, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/28881785/mir-486-5p-negatively-regulates-oncogenic-nek2-in-hepatocellular-carcinoma
#19
Shun-Jun Fu, Jian Chen, Fei Ji, Wei-Qiang Ju, Qiang Zhao, Mao-Gen Chen, Zhi-Yong Guo, Lin-Wei Wu, Yi Ma, Dong-Ping Wang, Xiao-Feng Zhu, Xiao-Shun He
NEK2 is a member of the NIMA-related family of serine/threonine centrosomal kinases. We analyzed the relationship between differential expression of NEK2 and hepatocellular carcinoma (HCC) patient outcomes after liver transplants. We also studied the microRNAs that affect NEK2 expression. Analysis of multiple microarrays in the Oncomine database revealed that NEK2 expression was higher in HCC tissues than adjacent normal liver tissues. High NEK2 expression correlated with tumor size, pathological grade and macro- and microvascular invasion...
August 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28881064/misdiagnosis-of-hepatocellular-carcinoma-in-patients-receiving-no-loco-regional-therapy-prior-to-liver-transplant-an-analysis-of-the-optn-explant-pathology-form
#20
Neil Mehta, Jennifer L Dodge, John P Roberts, Ryutaro Hirose, Francis Y Yao
Patients with T1 hepatocellular carcinoma (HCC) are not eligible for MELD exception for liver transplant (LT) in part due to a high rate of misdiagnosis (no HCC on explant). The likelihood of misdiagnosis for T2 HCC and factors associated with misdiagnosis are unknown. We analyzed the OPTN database including 5664 adults who underwent LT from 2012-2015 with MELD exception for T2 HCC, and searched for no evidence of HCC in the explant pathology file. We focused on those (n=324) receiving no local regional therapy (LRT) to evaluate the probability of no HCC found in explant...
September 7, 2017: Clinical Transplantation
keyword
keyword
28620
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"